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Chronic antigen-stimulation has been recurrently involved in the earlier stages of monoclonal B-
cell lymphocytosis, chronic lymphocytic leukemia and other B-cell chronic lymphoproliferative 
disorders. Among these individuals, expansion of ≥2 B-cell clones has been frequently reported; 
potentially, such coexisting clones have a greater probability of interaction with common 
immunological determinants. Here, we comparatively analyzed the B-cell receptor repertoire 
and the molecular profile, as well as the phenotypic, cytogenetic and hematological features of 
228 chronic lymphocytic leukemia-like and non-chronic lymphocytic leukemia-like clones 
between multiclonal (n=85 clones from 41 cases) versus monoclonal (n=143 clones) 
monoclonal B-cell lymphocytosis, chronic lymphocytic leukemia and other B-cell chronic 
lymphoproliferative disorders. The B-cell receptor of B-cell clones from multiclonal cases 
showed a slightly higher degree of HCDR3 homology than B-cell clones from monoclonal 
cases, in association with unique hematological (e.g. lower B-lymphocyte counts) and 
cytogenetic (e.g. lower frequency of cytogenetically altered clones) features usually related to 
earlier stages of the disease. Moreover, a subgroup of coexisting B-cell clones from individual 
multiclonal cases which were found to be phylogenetically related, showed unique molecular 
and cytogenetic features: they more frequently shared IGHV3 gene usage, shorter HCDR3 
sequences with a greater proportion of IGHV mutations and del(13q14.3), than other unrelated 
B-cell clones. These results would support the antigen-driven nature of such multiclonal B-cell 
expansions, with potential involvement of multiple antigens/epitopes. 
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B-cell chronic lymphoproliferative disorders (B-CLPD) usually show a monoclonal 
expansion of a (single) mature-appearing aberrant B-cell clone.1-4 However, patients diagnosed 
with composite lymphomas and other B-cell chronic lymphocytic leukemias – e.g. chronic 
lymphocytic leukemia (CLL) – have been reported in the literature for decades, particularly 
among immunocompromised subjects.5-7 Although early reports considered this phenomenon 
as a rare event, it might have been underestimated due to the need for sophisticated 
multidisciplinary approaches encompassing combined histopathology, cytomorphology, 
immunophenotypic and cytogenetic techniques and/or molecular analyses of purified cell 
populations.8 In fact, B-cell neoplasms consisting of two phenotypically distinct populations of 
clonally unrelated B-lymphocytes coexisting in the same patient (detected either simultaneously 
or at different time points during follow-up) have been reported in the literature,9,10 with an 
estimated overall frequency among B-CLPD patients of around 5%.11 Recently, it has also been 
shown that up to 20% of population-based non-CLL and CLL-like low count monoclonal B-cell 
lymphocytosis (MBLlo) cases may also carry two different unrelated B-cell clones.12-14 In 
addition, data from a small series suggest that the frequency of multiclonality could be 
particularly high among CLL-like MBL cases from CLL relatives, (4/6 cases analysed).12 
Altogether, these results support the existence of multiclonality in a significant proportion of both 
MBL cases and B-CLPD patients.  
Multiclonal MBL and B-CLPD cases may consist of expansions of ≥2 B-cell clones 
potentially associated with chronic antigen-driven immune responses.15-17 In fact, this is 
particularly frequent at the earlier MBLlo stages, which would further support the potential 
reactive nature of MBL among individuals with normal lymphocyte counts, prior to the stepwise 
acquisition of genetic alterations and progression to clinical MBL (MBLhi) and CLL.13,14,18,19 If this 
hypothesis holds true, specific antigenic determinants could potentially be more frequently 
shared between the coexisting B-cell clones of multiclonal cases than between the expanded B-
cells in different monoclonal MBL and B-CLPD patients, due to a greater probability of 
interaction with common immunological determinants. This might even be true when the 
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coexisting clones display clearly distinct immunophenotypic and cytogenetic, as well as clinical 
features.20-22 
In order to test this hypothesis, in the present study we compared the B-cell receptor 
(BCR) repertoire and molecular profile, as well as the phenotypic, cytogenetic and 
hematological features of CLL-like and non-CLL-like clones (n=228) from multiclonal (n=41 
cases) vs monoclonal cases (n=143, including both CLL and CLL-like MBL -n=128-, as well as 






Patients and samples. A total of 184 subjects with one (n=143 monoclonal cases) or ≥2 (n=41 
multiclonal cases) CLL/non-CLL B-CLPD (n=140) and/or CLL-like/non-CLL-like MBL (n=88) B-
cell clones -as defined by the World Health Organization criteria 2008- 23 were included. Binet 
staging24 of CLL subjects was retrospectively collected.  
  From the 41 multiclonal cases, 2 (5%) corresponded to healthy individuals with CLL-like 
MBLlo, 8 (19.5%) were CLL-like MBLhi cases, 23 (56%) had CLL and 8 (19.5%) had B-CLPD 
other than CLL; 4 of these latter cases showed coexistence of either one or two CLL-like MBL 
B-cell population(s). In 3/41 multiclonal cases, three coexisting B-cell populations were 
detected. From the 143 monoclonal cases, 13 (9%) corresponded to healthy adults with CLL-
like MBLlo, 26 (18%) were CLL-like MBLhi, 89 (62%) had CLL, 2 (1%) were non-CLL-like MBLlo, 
2 (1%) non-CLL-like MBLhi cases and 11 (8%) had other B-CLPD. The precise criteria used for 
the classification of MBLlo and MBLhi is detailed in Online Supplementary Methods. The 
age/gender distribution for each diagnostic group, is detailed in Supplementary Table 1. 
Peripheral blood samples were obtained from each subject after written informed 
consent was given, and the study was approved by the local ethics committees of the University 
Hospital of Salamanca and the Blood and Transplantation Center of Coimbra/Portuguese 
Institute of Blood and Transplantation, in accordance with the Helsinki Declaration of 1975, as 
revised in 2008.  
 
Immunophenotypic analyses. Immunophenotypic studies to screen for the presence and full 
characterization of clonal B-cell populations were performed by high-sensitive multiparameter 
flow cytometry on erythrocyte-lysed peripheral blood samples, according to previously 
described procedures18,25-29 which are also detailed in Online Supplementary Methods. All 
cases showed a clonal (imbalanced SmIgκ:SmIgλ ratio of >3:1 or <1:3) and/or an aberrant CD5+ 
B-cell population. 
 
Cytogenetic and molecular studies. Cytogenetic analyses were performed by multicolor 
interphase fluorescence in situ hybridization on slides containing FACS-purified and fixed 
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aberrant B-cells, as previously described in detail.18,30 In parallel, analysis of the patterns of 
rearrangement of the immunoglobulin heavy chain variable region genes (IGHV) and 
immunoglobulin K (IGKV) and λ (IGLV) light chain genes was performed for each FACS-purified 
B-cell clone 18,31-32 (see the Online Supplementary Methods section for detailed descriptions). 
To investigate the level of phylogenetic relationship among IGHV aminoacid sequences, a 
sequence distance tree was built using the neighbor-joining method implemented in the freely 
available Molecular Evolutionary Genetic Analysis (MEGA) software.33 Two different co-existing 
BCRs were considered as being phylogenetically related when their IGHV aminoacid 
sequences, going from framework region 1 to HCDR3 (both regions included) showed an 
identity ≥ 60%. This “identity” threshold was based on previously published concepts about the 
phylogeny of human IGHV genes based on their aminoacid sequences33, and on the minimum 
identity percentage observed in colocalized sub-branches (presumably with the highest 
evolutionary relationship33) of the sequence distance tree built in this study (see the Online 
Supplementary Methods section for more detailed descriptions). HCDR3-alignments were 
carried out for each multiclonal case whose co-existing B-cell clones showed HCDR3 regions 
with identical or one aminoacid differing lengths using the bioinformatic tools available at the 
web services of the European Bioinformatics Institute (EMBL-EBI Cambridge, UK). Through the 
EMBL-EBI tools, the identical aminoacids or those with analogous side-chain polarity per paired 
intra-case HCDR3-alignment were highlighted (see the Online Supplementary Methods section 
for more detailed descriptions). 
 
Statistical methods. For all statistical analyses the SPSS software program (SPSS 20.0, IBM 






Distribution and immunophenotypic features of B-cell clones. A total of 228 B-cell clones 
were identified. These corresponded to 143 B-cell clones (89 CLL, 11 non-CLL, 39 CLL-like 
MBL and 4 non-CLL-like MBL clones) from monoclonal cases and 85 B-cell clones (26 CLL, 14 
non-CLL, 40 CLL-like MBL and 5 non-CLL-like MBL clones) from multiclonal cases 
(Supplementary Table 2). The complete immunophenotypic and cytogenetic features of the 
individual clones of multiclonal cases are summarized in Supplementary Table 3. 
In 26/41 multiclonal cases, all coexisting B-cell clones showed a CLL-like phenotype, 
while in 11 of the remaining 15 cases, at least one CLL-like B-cell population coexisting with 
another non-CLL aberrant B-cell population was identified. In the remaining 4 cases, two distinct 
non-CLL-like B-cell clones were found (Supplementary Table 3). The distribution of all CLL/non-
CLL and CLL-like MBL/non-CLL-like MBL clones analyzed (from all monoclonal and multiclonal 
cases considered together) in the distinct diagnostic categories was as follows: 27 B-cell clones 
corresponded to CLL-like MBLlo, 52 to CLL-like MBLhi, 115 to CLL, 5 to non-CLL-like MBLlo, 4 to 
non-CLL-like MBLhi and 25 to non-CLL B-CLPD (Supplementary Table 2). The precise 
diagnoses of the B-cell clones from B-CLPD patients other than CLL are specified in the 
footnote of Supplementary Table 2.  
 
Overall size and BCR features of B-cell clones from multiclonal versus monoclonal MBL, 
CLL and other B-CLPD cases. The relative and absolute median number of peripheral blood 
clonal B-cells was significantly lower in multiclonal than in monoclonal cases (13% vs 45% and 
2,692 cells/µL vs 9,115 cells/µL, respectively; P=0.001). Of note, the absolute median number 
of CLL-like MBLhi and CLL B-cell clones were also significantly lower in multiclonal than in 
monoclonal cases (1,254 vs 2,464 cells/µL and 9,113 vs 18,600 cells/µL, respectively; P=0.004 
and P=0.02) (Supplementary Figure 1). In contrast, the absolute median number of peripheral 
blood CLL-like MBLlo B-cell clones was significantly higher in multiclonal than in monoclonal 
cases (79 vs 1 cells/ µL, P=0.002). No significant differences were found in the clone size 
between non-CLL like and non-CLL B-cell clones in multiclonal vs monoclonal cases 
(Supplementary Figure 1). In addition, the frequency of CLL-like MBL B-cell clones was 
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significantly higher in multiclonal than in monoclonal cases (47% vs 27%, respectively; 
P=0.002), whereas the frequency of CLL B-cell clones was higher in monoclonal vs multiclonal 
subjects (62% vs 31%, respectively; P=0.001). CLL B-cell clones from multiclonal and 
monoclonal CLL patients showed a similar distribution in Binet stage A vs Binet stages B/C 
(P>0.05). Of note, non-CLL B-cell clones were present at higher frequencies in multiclonal vs 
monoclonal cases (17% vs 8%, respectively; P=0.04) (Table 1). 
Regarding BCR features, a similar distribution of IGHV mutated and IGHV unmutated B-
cell clones was found in multiclonal vs monoclonal cases − 51/85 (60%) vs 84/139 (60%) and 
34/85 (40%) vs 55/139 (40%), respectively; Table 1 −. Despite this, the percentage of alignment 
of IGHV aminoacid sequences among B-cell clones from multiclonal cases (n=3,560 two by two 
comparisons of clonal IGHV aminoacid sequence) was slightly higher than that obtained among 
B-cell clones from monoclonal cases (n=8,891 comparisons): median of 52% vs 50%, 
respectively; (P=0.001; Table 1).  
 
Cytogenetic features of B-cell clones from multiclonal versus monoclonal MBL and B-
CLPD cases. The frequency of CLL-like MBL and CLL clones from multiclonal cases that 
showed cytogenetic alterations was significantly lower than that found among CLL-like MBL and 
CLL clones from monoclonal cases: 27/66 (41%) vs 77/128 (60%), respectively (P=0.02). 
Likewise, the proportion of CLL-like B-cell clones showing coexistence of ≥2 cytogenetic 
alterations was also significantly lower in multiclonal than in monoclonal cases − 8/66 (12%) vs 
32/128 (25%); P=0.047 −; this was specially true among B-cell clones from CLL patients − 2/26 
(8%) vs 29/89 (33%), respectively; P=0.03 – (Table 2). 
Regarding each specific cytogenetic alteration, only a decreased frequency of CLL-like 
B-cell clones with del(13q14) involving the RB1 gene and a lower percentage of del(13q14)+ 
cells was found in multiclonal vs monoclonal cases − frequency of del(13q14)+ clones − of 5% 
vs 15% with a median of del(13q14)+ cells of 55% vs 86%, respectively; P=0.01) (Table 2). Of 
note, these differences were mostly due to the lower frequency of B-cell clones with del(13q14) 
(4% vs 19%, P=0.01) found among CLL clones from multiclonal vs monoclonal cases (Table 2).  
No statistically significant differences were observed in the cytogenetic patterns of non- 
CLL B-cell clones from multiclonal vs monoclonal cases, which is probably due to the relatively 
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low number of non-CLL clones included in the study; the precise cytogenetic alterations found in 
non-CLL / non-CLL-like MBL cases are shown in Supplementary Tables 3 and 4. In turn, the 
overall cytogenetic features of non-CLL like B-cell clones from multiclonal (N=19; 3 non-CLL 
MBLlo, 2 non-CLL MBLhi, 14 non-CLL B-cell clones) vs monoclonal (N=15; 2 non-CLL MBLlo, 2 
non-CLL MBLhi, 11 non-CLL B-cell clones) subjects were similar, as regards both the frequency 
of cytogenetically altered clones (6/19, 32% and 6/15, 40%) and the percentage of cases with 
≥2 genetic alterations − 2/19 (11%) vs 2/15 (13%) – (Supplementary Tables 3 and 4). 
 
Molecular characteristics of the BCR of B-cell clones from multiclonal versus 
monoclonal MBL and B-CLPD cases. The molecular profile of the BCR of CLL-like MBLlo, 
MBLhi and CLL B-cell clones and of B-cell clones other than CLL from multiclonal vs monoclonal 
cases was very similar (Table 3 and Supplementary Table 5). No statistically significant 
differences in multiclonal vs monoclonal VH gene usage were found for most groups. Despite 
this general behavior, CLL-like MBLhi B-cell clones from multiclonal cases less frequently 
showed usage of the DH1, DH4 and DH7 gene families than B-cell clones from monoclonal 
cases; in addition, JH6 genes were also less frequently used by CLL B-cell clones from 
multiclonal vs monoclonal cases (Table 3). Overall, 33 functional IGHV gene rearrangements 
were identified from which 12 (V4-34, V3-23, V3-48, V3-30, V1-69, V3-21, V4-39, V3-33, V3-11, 
V3-53, V1-2, V3-7) were highly represented among the B-cell clones (≥5% of all B-cell clones 
corresponding to ≥4 and ≥5 B-cell clones sharing the same IGHV gene in multiclonal and 
monoclonal cases, respectively) (Figure 1A). Interestingly, 11 of these IGHV genes were found 
at similar frequencies within the clones of multiclonal vs monoclonal cases, while the V3-33 
gene was typically associated with multiclonal cases (6% vs 1%, P=0.03). Regarding IGHD 
genes, no significant differences were observed between B-cell clones from multiclonal and 
monoclonal cases, the D3-3, D5-12, D3-10, D6-19, D2-15, and D2-2 genes being the most 
frequently used and shared by both groups of B-cell clones (Figure 1B). Among IGHJ genes, 
significant differences were only observed for the JH6 gene, which was more frequently used in 
monoclonal cases (40% vs 26%, P= 0.03) (Figure 1C). 
Except for slightly longer LCDR3 sequences of the IGKV and IGLV genes found among 
B-cell clones from multiclonal versus monoclonal cases, specially among CLL-like MBLhi clones 
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(Table 3), no other significant differences were found in the molecular characteristics of the 
immunoglobulin light chain genes, neither among CLL-like nor non-CLL like B-cell clones from 
multiclonal vs monoclonal cases (Table 3 and Supplementary Table 5). Regarding IGKV and 
IGLV genes, only the VK1-33 gene was associated with multiclonal cases (6% vs 0%, P=0.02) 
(Figure 1D) 
 
Molecular features of phylogenetically related BCRs of B-cell clones from multiclonal 
cases. Thirty-two of the 85 B-cell clones from individual multiclonal cases were phylogenetically 
closely related and had exactly the same IGHV family (IGHV3 in 28 B-cell clones and IGHV4 in 
4 B-cell clones) (Figure 2). Of note, this subgroup of B-cell clones frequently showed IGHV3 
gene usage (28/85, 33%) and they displayed shorter HCDR3 sequences than other (multiclonal 
and monoclonal) B-cell clones − 13 (6-25) vs 17(9-26) and 16 (8-32) aminoacids; P=0.001 and 
P=0.004, respectively −; in addition, they also showed a higher frequency of del(13q14.3) 
compared to B-cell clones from multiclonal cases expressing phylogenetically unrelated IGHV 
families (41% vs 17%, respectively; P=0.05). Moreover, a slightly higher frequency of 
multiclonal cases whose coexisting clones were cytogenetically altered was found among 
phylogenetically closely related clones vs phylogenetically unrelated clones from multiclonal 
cases (53% vs 34%, respectively; P=0.06). Interestingly, a trend towards an increased 
percentage of IGHV mutated B-cell clones among phylogenetically related B-cell clones from 
multiclonal cases compared to other B-cell clones from multiclonal cases, was also found (70% 
vs 54%, respectively; P=0.1). Interestingly, most of the co-existing phylogenetically related 
clones had a CLL-like phenotype (10/16 cases, identified in Supplementary Table 3 with the ¶ 
symbol), while in 4/16 multiclonal cases, one CLL-like B- cell clone coexisted with one non-CLL 
B-cell clone, (2 marginal zone lymphomas, 1 lymphoma of mucosa-associated lymphoid tissue 
and 1 hairy cell leukemia clones from cases 29, 32, 37 and 38, also identified in Supplementary 
Table 3 with the ¶ symbol). In a minority of cases (2/16), the two co-existing phylogenetically 
related clones were both non-CLL like, their phenotype being consistent with follicular 
lymphoma (case 16¶, in Supplementary Table 3) and lymphoma of mucosa-associated 




Homology of the HCDR3 region between B-cell clones coexisting in multiclonal cases vs 
non-coexisting (monoclonal) B-cell clones. The HCDR3 aminoacid sequence from 
coexisting B-cell clones had the same length or it just differed in one aminoacid in 8/41 
multiclonal cases analyzed (19%) (Table 4A). The homology of all these case-paired HCDR3 
regions was calculated as the number of identical aminoacids or aminoacids with an analogous 
side-chain polarity (excluding the anchor second-CYS104 (C_) and the J-TRP 118 (_W) 
aminoacid positions that delineate the HCDR3 region) divided by the corresponding HCDR3 
length (Table 4A). It is worth noting that the aminoacid composition of HCDR3 sequences of the 
same length (±1 aminoacid) that belonged to the same or evolutionary, highly-related, VH 
families (e.g. VH3-48, VH3-21, VH3-11)33 (n=57) from monoclonal cases (Supplementary Table 
6) showed a tendency towards a lower homology than that of multiclonal cases: median of 37% 
(range: 11% to 71%) vs 50% (range: 26% to 64%), respectively; (P=0.1). Since stereotyped 
sequences are widely represented in CLL,34 we further analyzed the frequency of stereotyped 
HCDR3 sequences in multiclonal cases (Table 4B) vs. monoclonal cases (Table 4C). 
Interestingly, the number of multiclonal cases showing the same or highly similar stereotyped 
HCDR3 sequences was significantly higher than that of monoclonal cases: 8/41 (19%) vs 
11/143 (8%), respectively, (P=0.001). Furthermore, the aminoacid composition of HCDR3 
sequences from monoclonal cases with stereotyped HCDR3 sequences showed clearly less 
identical and/or conserved positions than those found among multiclonal cases (underlined 





Multiclonal expansions of phenotypically aberrant B-cell clones (MBLlo) have been 
reported as frequently present in the general population35; of note, multiclonal expansions of 
immunophenotypically normal B-cells can also be found in non-malignant diseases, such as 
autoimmune disorders and inflammatory responses against several infectious agents (e.g. 
Helicobacter pylori, hepatitis C virus).36,37 Whether clonal expansions of aberrant B-cells found 
in otherwise healthy individuals (MBLlo) reflect a prominent reactive process against potent 
antigenic stimuli with unknown clinical relevance, or they represent an early (multi)clonal 
manifestation of a BCR-dependent neoplastic event, still remains to be established. In this 
regard, it should be noted that between 30% and 40% of such cases show cytogenetic changes 
shared by MBL and CLL, e.g. del(13q). Of note, among other large structural chromosomal 
alterations, clonal mosaicism involving del(13q14) has also been recently found in peripheral 
blood cell populations from otherwise healthy individuals, particularly among subjects with more 
advanced age (around 2-3% in the elderly), but its potential relationship with MBL and CLL 
remains unknown.38,39 Compared to the typical (monoclonal) MBL and B-CLPD, coexisting B-
cell clones from multiclonal MBL and B-CLPD may potentially have a greater probability of 
interacting with common immunological determinants. However, there is still little information 
about the potential existence of shared BCR features in cases showing ≥2 coexisting B-cell 
clones vs monoclonal cases.  
In the present study, we analyzed for the first time the molecular and cytogenetic 
features of a large group (n=85) of coexisting, but unrelated, B-cell clones from a series of 41 
multiclonal MBL and B-CLPD cases, in comparison to 143 monoclonal cases. Overall, the 
former clones more frequently showed cytogenetic and hematological features which are typical 
of the earliest MBL stages and/or initial phases of CLL.18,36,37 Accordingly, B-cell clones from 
multiclonal cases more frequently corresponded to MBL cases, whereas B-cell clones from 
monoclonal cases were more frequently found to correspond to overt CLL. Of note, these 
findings do not contradict the apparent discrepancy between such association and our previous 
observation among CLL patients of a worse clinical outcome for multiclonal cases carrying non-
CLL clones,11 as this latter study was restricted to overt CLL cases. In addition, multiclonal 
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cases were also associated with lower clonal B-cell counts in peripheral blood, a lower number 
of cytogenetically altered clones, particularly of those carrying del(13q), and a decreased 
frequency of clones with ≥2 alterations. Of note, clonal expansions of non-CLL like B-cell clones 
were also more frequently observed in multiclonal than in monoclonal cases, such expansions 
corresponding mainly to indolent lymphomas (e.g. marginal zone lymphoma) which have been 
associated with chronic immune responses.40,41  
Altogether, these results support the notion that the presence of multiple B-cell clones in 
the same individual more closely reflects the earlier stages of the disease. If this holds true and 
chronic antigen stimulation is involved in the onset of MBL and B-CLPD -as it has been recently 
suggested for MBL, based on epidemiological studies-,42 it could be hypothesized that B-cell 
clones coexisting in multiclonal cases would show more closely related BCR features than B-
cell clones from monoclonal cases. In this regard, our results point out the existence of a slightly 
higher level of HCDR3 homology among B-cell clones from multiclonal vs monoclonal cases. In 
fact, in around one fifth of all multiclonal cases, the co-existing B-cell clones showed a high 
homology in their HCDR3 aminoacid sequences; this also hold true when we compared the 
homology of the HCDR3 sequences of these multiclonal against those of monoclonal cases 
whose B-cell receptors were restricted to the same and/or ontogenetically related IGHV families. 
In addition, the frequency of stereotyped HCDR3 was also higher in multiclonal vs. monoclonal 
cases. Such more closely related BCR features would be found independently of whether 
common antigens or superantigens are specifically involved, although the former would 
potentially lead to a higher HCDR3 homology, whereas superantigens could contribute to a 
greater frequency of usage of specific IGHV, IGHD and/or IGHJ genes.13,43  
In the present study, we found a similar frequency of IGHV gene usage between 
coexisting multiclonal and non-coexisting monoclonal B-cell clones in association with a lower 
frequency of DH1, DH4 and DH7 as well as JH6 families in multiclonal vs monoclonal B-cell 
clones. Overall, these results suggest that no single antigen or superantigen is involved in 
common in MBL and B-CLPD. This is further supported by the relatively low percentage of 
alignment (≈50%) of the IGHV aminoacid sequences observed among the different clonal B-cell 
populations analyzed, since such potential antigens -including superantigens- would require 
interaction with highly conserved sites at the IGHV/HCDR3 regions of the BCR.44 Interestingly 
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however, the higher representation of DH1, DH4, DH7 and JH6 IGH gene segments in 
monoclonal vs multiclonal B-cell clones, together with the slightly higher levels of HCDR3 
homology observed among coexisting (multiclonal) vs non-coexisting (monoclonal) B-cell clones 
from MBL, CLL and other B-CLPD cases, would indicate that still non-random selection of 
specific HCDR3, DH and JH segments could exist in the MBL and CLL repertoire of both 
multiclonal and monoclonal cases, which could reflect antigen-driven selection and expansion of 
specific B-cell clones, both at the MBL and/or CLL stages.45  
In this regard, based on the phylogenetic proximity of their BCR, we could further 
identify within the B-cell clones from multiclonal cases, a considerably represented subgroup of 
B-cell clones showing preferential usage of IGHV3 genes and shorter HCDR3 sequences 
carrying a significantly higher number of IGHV mutations vs the unrelated clones. These results 
further support the involvement of a common antigen, at least in this specific subset of cases.46 
Interestingly, these “phylogenetically-related” B-cell clones coexisting in multiclonal cases 
showed a significantly higher frequency of del(13q) than B-cell clones expressing other IGHV 
genes. These observations further suggest that the BCR features of this subset of coexisting 
multiclonal B-cell clones could also contribute to determine the probability and/or type of 
cytogenetic progression occurring at the earliest stages of the disease, as previously suggested 
by our group18 and others.47,48 Further long-term, longitudinal studies are required to confirm this 
hypothesis, since multiple productive IGHV gene rearrangements may also underline clonal drift 
leading to selection for more aggressive clones whose proportions would change over time.49 
In summary, based on the molecular features of the BCR and the cytogenetic profile of 
B-cell clones from the multiclonal vs monoclonal MBL, CLL and other B-CLPD cases here 
analyzed, it may be concluded that multiclonality is typically associated with early stages of B-
CLPD, at the same time it appears to more closely reflect an antigen-driven nature of MBL and 
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Table 1. Peripheral blood (PB) B-cell counts and BCR features of multiclonal vs. monoclonal B-cell clones from B-cell chronic 








N. of  PB clonal B cells(x106/L)* 2,692 (0.6-156,168)a 9,115 (0.1-369,288) 5,530 (0.1-369,288) 
% of PB clonal B cells from WBC* 13% (0.1%-89%)a 45% (0.002%-97%) 35% (0.001%-97%) 
CLL like MBLlo B-cell clones 14/85 (16%) 13/143 (9%) 27/228 (12%) 
CLL like MBLhi B-cell clones 26/85 (31%)a 26/143 (18%) 52/228 (38%) 
CLL B-cell clones 26/85 (31%)a 89/143 (62%) 113/228 (50%) 
 CLL-stage A clones 12/20 (60%) 53/89 (60%) 65/109 (60%) 
 CLL-stage B/C clones 8/20 (40%) 36/89 (40%) 44/109 (40%) 
Non-CLL like MBL B-cell clones 5/85 (6%) 4/143 (3%) 9/228 (4%) 
Non-CLL B-cell clones 14/85 (17%)a 11/143 (8%) 25/228 (11%) 
IGHV mutated CLL-like  B-cell clones 40/66 (61%) 76/128 (59%) 116/194 (60%) 
IGHV mutated non-CLL-like  B-cell 
clones 
11/19 (58%) 8/15 (53%) 19/34 (56%) 
%  alignment of  IGHV aa sequences  
between coexisting B-cell clones* 51% (38%-79%) AN 51% (38%-79%) 
% alignment of  IGHV aa sequences 
between each B-cell clone and the other 
clones* 
52% (31%-100%)a 50% (29%-100%) 51% (29%-100%) 
Results expressed as number of B-cell clones and percentage between brackets or as *median value (range). PB, peripheral blood; WBC, 
white blood cells; CLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MBLlo, low count monoclonal B-cell lymphocytosis; 
IGHV, immunoglobulin heavy chain variable region genes; CLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MBLhi, clinical 
monoclonal B-cell lymphocytosis; aa, aminoacids. NA, not appropriate. aStatistically significant differences (P < 0.05) found between clones 
from multiclonal vs monoclonal cases. Information about the parameters included in this table is separately displayed for CLL-like vs non-
CLL-like clones in Supplementary Table 7. 
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Table 2. Cytogenetic features of CLL-like MBLlo, MBLhi and CLL B-cell clones from monoclonal vs multiclonal cases. 
Cytogenetic alterations 

















No. of cytogenetically altered clones 2/14 (14%) 6/13 (46%) 13/26 (50%) 13/26 (50%) 12/26 (46%) 58/89 (65%) 27/66 (41%)b 77/128 (60%) 
No. of clones with ≥2 alterations 1/14 (7%) 1/13 (8%) 5/26 (19%) 2/26 (8%) 2/26 (8%)a 29/89 (33%) 8/66 (12%)b 32/128 (25%) 
Type of cytogenetic changes 
        
No. of del(13q)+ clones (%)  
% del(13q)+ cells * 
























No. of del(13q14.3)+ clones (%) 
% del(13q14.3)+ cells * 






















No. of del(13q14)+ clones (%) 





















No. of trisomy 12+ clones (%) 























No. of t(14q32)+ clones (%) 





















No. of del(11q)+ clones (%) 




















No. of del(11q22.3)+ clones (%) 




















No. of del(11q23)+ clones (%) 



















No. of del(17p13.1)+ clones (%) 



















Results expressed as number of clones with cytogenetic changes from all clones in the corresponding group (percentage) or as *median values of altered 
cells/clone (range). In seven clones (1 multiclonal MBLlo, 3 monoclonal and 3 multiclonal CLL clones) biallelic del(13q14.3) was detected, and polysomy was 
found  in 1 multiclonal CLL clone. Statistically significant differences found between multiclonal vs monoclonal B-cell clone groups for aCLL clones (P=0.01) and 







Table 3. Molecular characteristics of the B-cell receptor (BCR) of chronic lymphocytic leukemia (CLL)-like monoclonal B-cell 
lymphocytosis (MBL)lo, MBLhi and CLL B-cell clones from monoclonal versus multiclonal cases.  


















HCDR3 length* (N. of aa) 15 (6-22) 13 (11-20) 16 (8-23) 17 (9-26) 17 (11-26) 18 (8-32) 17 (6-26) 17 (8-32) 
VH families 
VH1 2/14 (14%) 2/13 (15%) 3/26 (12%) 4/25 (16%) 4/26 (15%) 25/87 (29%) 9/66 (14%) 31/125 (25%) 
VH3 9/14 (65%) 9/13 (69%) 15/26 (58%) 16/25 (64%) 11/26 (42%) 36/87 (41%) 35/66 (53%) 61/125 (49%) 
VH4 2/14 (14%) 2/13 (15%) 6/26 (23%) 3/25 (12%) 9/26 (35%) 23/87 (27%) 17/66 (26%) 28/125 (22%) 
VH2, VH5, VH6 1/14 (7%) 0/13 (0%) 2/26 (8%) 2/25 (8%) 2/26 (8%) 3/87 (3%) 5/66 (7%) 5/125 (4%) 
 
        
DH families 
DH1, DH4, DH7 3/14 (21%) 2/13 (15%) 1/26 (4%)a 6/24 (25%) 6/26 (23%) 11/86 (13%) 10/66 (15%) 19/123 (16%) 
DH2 2/14 (14%) 3/13 (23%) 5/26 (19%) 7/24 (29%) 4/26 (15%) 15/86 (17%) 11/66 (17%) 25/123 (20%) 
DH3 3/14 (21%) 2/13 (15%) 9/26 (35%) 7/24 (29%) 13/26 (50%) 36/86 (42%) 25/66 (38%) 45/123 (37%) 
DH5 2/14 (14%) 3/13 (23%) 6/26 (23%) 2/24 (8%) 3/26 (12%) 9/86 (11%) 11/66 (17%) 14/123 (11%) 
DH6 4/14 (29%) 3/13 (23%) 5/26 (19%) 2/24 (8%) 0/26 (0%) 15/86 (17%) 9/66 (13%) 20/123 (16%) 
 
        
JH genes 
JH1, JH2, JH3, JH5 3/14 (21%) 2/13 (15%) 7/26 (27%) 7/24 (29%) 9/26 (35%) 14/86 (16%) 19/66 (29%) 23/123 (19%) 
JH4 6/14 (43%) 7/13 (54%) 13/26 (50%) 8/24 (33%) 10/26 (38%) 34/86 (40%) 29/66 (44%) 49/123 (40%) 
JH6 5/14 (36%) 4/13 (31%) 6/26 (23%) 9/24 (38%) 7/26 (27%)a 38/86 (44%) 18/66 (27%)a 51/123 (41%) 
 
        
LCDR3 length* (N. of aa) 9 (8-13) 10 (8-10) 10 (8-12)a 9 (7-12) 10 (8-15) 9 (5-12) 10 (8-15)a 9 (5-12) 
VK families 
VK1 0/6 (0%) 1/4 (25%) 6/14 (43%) 3/12 (25%) 6/12 (50%) 23/48 (48%) 12/32 (38%) 27/64 (42%) 
VK2, VK5, VK6 1/6 (17%) 0/4 (0%) 1/14 (7%) 3/12 (25%) 2/12 (17%) 8/48 (17%) 4/32 (13%) 11/64 (17%) 
VK3, VK4 5/6 (83%) 3/4 (75%) 7/14 (50%) 6/12 (50%) 4/12 (33%) 17/48 (35%) 16/32 (50%) 26/64 (41%) 
 
        
JK genes 
JK1, JK3, JK5 3/6 (50%) 1/4 (25%) 5/14 (36%) 7/12 (58%) 5/12 (42%) 21/47 (45%) 13/32 (40%) 29/63 (46%) 
JK2 2/6 (33%) 2/4 (50%) 8/14 (57%) 3/12 (25%) 4/12 (33%) 10/47 (21%) 14/32 (44%) 15/63 (24%) 
JK4 1/6 (17%) 1/4 (25%) 1/14 (7%) 2/12 (17%) 3/12 (25%) 16/47 (34%) 5/32 (16%) 19/63 (30%) 
 
        
Vλ families 
Vλ3 2/3 (67%) NA 1/7 (14%) 0/7 (0%) 2/7 (29%) 8/25 (32%) 5/17 (29%) 8/32 (25%) 
Other 1/3 (33%) NA 6/7 (86%) 7/7 (100%) 5/7 (71%) 17/25 (68%) 12/17 (71%) 24/32 (75%) 
 
        
Jλ genes 
Jλ1 1/3 (33%) NA 0/7 (0%) 0/7 (0%) 4/7 (57%) 6/21 (71%) 5/17 (29%) 6/28 (21%) 
Other 2/3 (67%) NA 7/7 (100%) 7/7 (100%) 3/7 (43%) 15/21 (29%) 12/17 (71%) 22/28 (79%) 
         
IGHV mutational status 
        
Mutated IGHV 9/14 (64%) 8/11 (73%) 17/26 (65%) 20/25 (80%) 14/26 (54%) 46/86 (54%) 40/66 (61%) 74/122 (61%) 
Unmutated IGHV 5/14 (36%) 3/11 (27%) 9/26 (35%) 5/25 (20%) 12/26 (46%) 40/86 (47%) 26/66 (39%) 48/122 (39%) 
Results expressed as number of B-cell clones from all clones in the corresponding group (percentage) or as *median (range). CLL, chronic lymphocytic leukemia/small 
lymphocytic lymphoma; MBL, monoclonal B-cell lymphocytosis; BCR, B-cell receptor; HCDR3, heavy chain complementarity-determining region 3; LCDR3, light chain 
complementarity-determining region 3; aa, amino acid. NA, not analyzed; a statistically significant differences found between groups of clones from multiclonal vs 





Table 4. Multiclonal cases with coexisting B-cell clones sharing HCDR3 features (A). Multiclonal (B) and monoclonal (C) cases 
with B-cell clones showing stereotyped HCDR3 aminoacid sequences. 
A. Multiclonal cases with coexisting B-cell clones showing identical or one aa differing length of HCDR3 regions, 
and analogous composition of aa in some parallel positions. 
















































C_ARAGGYCNSGSCRGAPRWYFDL_W (22) 32 
Aminoacids with analogous side-chain polarity (highlighted in gray): case 8 (I, V and F, M), case 11 (A, V and M, 
F), case 14 (L, F), case 22 (L, W; S, T and F, M), case 29 (A, V), case 31(L, F and H, Y), case 32 (T, S), case 33 
(W, C) (EMBL-EBI Cambridge, UK). All cases had coexisting B-cell clones with CLL-like phenotype, except case 
29 (one B-cell clone corresponded to a MALT lymphoma-like phenotype), cases 32 and 33 (both had one B-cell 
clone with a MZL-like phenotype). MALT, lymphoma of mucosa-associated lymphoid tissue; MZL, marginal zone 
lymphoma. #Number of aminoacids with analogous side-chain polarity (excluding the delineating C_ and _W 
positions)/HCDR3 length*100 
B. Multiclonal cases with B-cell clones showing stereotyped HCDR3 sequences. 

























Cases 1 and 2; 9 and 15; 21 and 35; 22 and 40 showed a highly similar HCDR3 sequence; the underlined 
aminoacids were different. All the listed B-cell clones had a CLL-like phenotype. 
C. Monoclonal cases with B-cell clones showing stereotyped HCDR3 sequences. 


































Cases 117 and 134; 207, 208 and 210; 187 and 215; 180 and 204; 196 and 198 showed a highly similar HCDR3 




Legend to Figures 
 
Figure 1. Frequency of IGHV (panel A), IGHD (panel B), IGHJ (panel C) and both IGKV and 
IGLV (panel D) genes in multiclonal and monoclonal CLL versus non-CLL like B cell 
clones. Diagrams show the relative frequency of each IG gene in multiclonal compared to 
monoclonal B-cell clones (black and white bars, respectively). *Statistically significant 
differences were found between the multiclonal vs monoclonal subgroups (P < 0.05). 
 
Figure 2. Sequence distance cladogram of IGHV gene usage in CLL-like and non-CLL like 
B-cell clones from multiclonal (dark colored bars in the outside circle) and monoclonal 
(light colored bars in the outside circle) cases. Five major branches were found in the 
sequence distance cladogram (i.e VH1, VH5, VH3, VH2-VH6, VH4). B-cell clones from 
individual multiclonal cases are represented by numbers; from them, those phylogenetically 
closely related B-cell clones, which share the same IGHV family, are specifically identified by 
bold numbers in the inner part of the circle and the symbol ¶. Of note, B-cell clones from 
multiclonal cases 14¶, 16¶ and 35¶ belong to closely located sub-branches of the cladogram, 
having their IGHV sequences an aminoacid identity of 79%, 76% and 69%, respectively. In turn, 
B-cell clones from the multiclonal case 32¶ belong to the VH4 major branch with IGHV 
sequences whose aminoacid identity is of 69%. Finally, the other B-cell clones from multiclonal 
cases – cases 2¶, 11¶, 15¶, 18¶, 19¶, 27¶, 29¶, 31¶, 34¶, 37¶, 38¶ and 40¶– belong to the VH3 
major branch, having IGHV sequences with an aminoacid identity which is > 60% (–68%, 73%, 









Patients: diagnostic criteria for MBL. MBL was defined by the presence of small clones of aberrant B-
cells in the peripheral blood (PB), with a clonal B-cell count below the threshold for diagnosis of CLL (< 5.0 
× 109 cells/L) (Br J Haematol. 2005;130(3):325-32). A MBL case was subclassified as “low count” MBL 
(MBLlo) when the absolute number of clonal B-lymphocytes was less than 200 cells/µL in PB and as “high 
count” MBL (MBLhi) when this number ranged between ≥200 and <5,000 clonal CLL-like B-cells/µL of PB.18 
Immunophenotypical analyses. Immunophenotypic studies to screen for the presence and full 
characterization of clonal B-cell populations were performed on erythrocyte-lysed PB samples according to 
procedures which have been previously described in detail.18,25 PB white blood cells (WBC) were 
systematically stained with the following monoclonal antibody (MAb) combinations following the EuroFlow 
recommendations:26,27 1) CD20-Pacific Blue (PacB), CD45-Pacific Orange (PacO), CD8-fluorescein 
isothiocyanate (FITC) plus anti–SmIgλ-FITC, CD56-phycoerythrin (PE) plus anti–SmIgκ-PE, CD4-peridin 
chlorophyll protein-cyanin 5.5 (PerCPCy5.5), CD19-PE-cyanin 7 (PECy7), CD3-allophycocyanin (APC) and 
CD38-Alexa Fluor 700 (AF700) – EuroFlow lymphocyte screening tube (LST) –;27 2) CD20-PacB, CD45-
PacO, CyBcl2-FITC, CD23-PE, CD19-PerCPCy5.5, CD10-PECy7, CD5-APC and CD38-AF700, and; 3) 
CD20-PacB, anti–SmIgλ-FITC, anti–SmIgκ-PE, CD19-PerCPCy5.5, CD10-PECy7 and CD5-APC. All cases 
showed a clonal (imbalanced SmIgκ:SmIgλ ratio of >3:1 or <1:3) and/or an aberrant CD5+ B-cell population 
for the above MAb combinations18; in every case, the phenotypic study was extended with additional 5- and 
6-color stainings, as reported elsewhere.28 
Data acquisition for ≥5x106 leucocytes/tube was performed in FACSCanto II flow cytometers (BD) using 
the FACSDiva software (V6.1; BD). Instrument setup, calibration and daily monitoring were performed 
according to the EuroFlow protocols.26 For data analysis, the InfinicytTM software (Cytognos SL, 
Salamanca, Spain), was used. The minimum number of clustered events required to define a B-cell 
population was of 50 cells. 
Purification of B-cell populations. In all cases studied, each sIg light chain restricted and phenotypically 
aberrant B-cell population identified was purified in a FACSAria II flow cytometer (BD). In those samples 
(n=41) containing ≥2 aberrant B-cell populations, discrimination among them was based on their distinct 
patterns of expression for ≥1 of the B-cell markers analyzed, as described elsewhere.29 The clonal nature 
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of each FACS-purified B-cell population (purity: 98%±0.8%) was assessed by both cytogenetic and 
molecular techniques, as described below. 
Cytogenetic and molecular studies. The presence of those cytogenetic alterations commonly associated 
with CLL and other non-CLL B-CLPD was investigated by multicolor interphase fluorescence in situ 
hybridization (iFISH) on slides containing FACS-purified and fixed aberrant B-cells, as previously described 
in detail.18,30 The following DNA probes purchased from Vysis Inc. (Downers Grove, IL, USA) allowed the 
detection of gains/losses and/or chromosomal translocations involving specific genes and chromosomal 
regions: CEP6 DNA probe conjugated with spectrum orange (SO), CEP12 DNA probe conjugated with SO, 
LSI ATM (11q22.3) conjugated with SO, LSI MLL (11q23) dual color probe, LSI p53 (17p13.1) conjugated 
with SO, LSI13/RB1 gene (13q14) conjugated with spectrum green, LSI D13S25 (13q14.3) conjugated with 
SO, LSI BCL6 (3q27) dual color, LSI MALT1 (18q21) dual color, LSI IgH (14q32) dual color, LSI IGH/CCN1 
t(11;14)(q13;q32.3) dual color, LSI IGH/bcl2 t(14;18)(q32;q21) dual color probe and IGH/MYC/CEP8 (8q24) 
tri-color probe. 
In parallel, analysis of the patterns of rearrangement of the immunoglobulin heavy chain variable region 
genes (IGHV) and immunoglobulin K (IGKV) and λ (IGLV) light chain genes was performed for each FACS-
purified B-cell clone. Extraction and purification of genomic DNA, PCR amplification, as well as sequencing, 
and analysis of V, (D), J gene sequences were performed following well-established protocols, which have 
been described in detail elsewhere.18,31,32 Forward (F) and reverse (R) sequences were aligned into a 
single resolved sequence and then aligned with germline sequences using the IMGT database and tools 
(http://imgt.org). For MBLlo clones, whole genomic amplification (WGA) was performed prior to analysis, 
using the RepligRUltraFast Mini kit (Qiagen, Valencia, CA) as per the recommendations of the 
manufacturer. For each FACS-sorted B-cell population, only in-frame rearrangements were evaluated. 
Sequences containing >2% deviation from the germline sequence were considered as being somatically 
mutated. 
Each deduced "IMGT/V-QUEST aminoacid (aa) sequence" corresponding to individual IGHV gene 
sequences from purified B-cell clones from both monoclonal and multiclonal cases was aligned using the 
bioinformatic tools available at the web services of the European Bioinformatics Institute (EMBL-EBI 
Cambridge, UK). More than 12,400 alignments of IGHV aminoacid sequences, with a coverage ranging 
from framework region (FR) 1 to the HCDR3 region (both regions included) were obtained for all B-cell 
clones (a total of 8,891 alignments within the monoclonal and 3,560 alignments within the multiclonal 
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groups of cases).Then, the percentage of alignment of IGHV aminoacid sequences obtained after two-by-
two comparisons between the distinct B-cell clones, was calculated for every pair of B-cell clones. Finally, 
each single paired-alignment obtained -8,891 and 3,560 in monoclonal vs. multiclonal cases, respectively- 
was included in a final database, to calculate the median and range of the total IGHV aminoacid alignment 
percentages and to calculate the statistical significance of their differences observed between the two 
groups (p-values). 
To investigate the level of phylogenetic relationship among IGHV aminoacid sequences corresponding 
to distinct clones from multiclonal cases, as well as monoclonal cases, a sequence distance tree was built 
using the neighbor-joining method implemented in the freely available Molecular Evolutionary Genetic 
Analysis (MEGA) software (version 5.2, http://www.megasoftware.net).33 Examination of the different 
branches of the sequence distance tree allowed the distinction of multiclonal cases whose clones had 
IGHV aminoacid sequences phylogenetically closer than others. Thus, sequences in the same major 
branch were guaranteed to exhibit ≥50% aminoacid identity (from FR1 to HCDR3, both regions included).33 
As might be expected, sequences in sub-branches emerging from the same major branch exhibit even 
more aminoacid identity, ranging from 60% to 99%. In our analysis, those co-existing B-cell clones with 
IGHV aminoacid sequences that belonged to the same major branch with >60% aminoacid identity or 
belonged to close located sub-branches were assumed to be “phylogenetically” related sequences. 
Those HCDR3 regions with an identical length or a length differing in one aminoacid were (case-paired) 
analyzed using the EMBL-EBI tools to determine those positions which had an identical or conserved 
composition in terms of “hydropathy”, “volume” and “chemical characteristics” as outlined in the IMGT 
classification of aminoacids (J Mol Recognit. 2004;17:17-32). 
Statistical methods. Comparisons between groups were performed with either the nonparametric Kruskal-
Wallis and Mann-Whitney U tests (for continuous variables) or the Pearson’s 2 and Fisher exact tests (for 
categorical variables) using the SPSS software/version 20.0 (IBM SPSS Statistics, IBM, Armonk, NY, 
USA). P values < 0.05 were considered to be associated with statistical significance. 
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Supplementary Table 1. Age and gender features of subjects included in the study. 
  Diagnostic subgroups 
  CLL and CLL-like MBL Non-CLL B-CLPD and non-CLL MBL 
 Age/Gender Features MBLlo MBLhi CLL MBLlo MBLhi Non-CLL 
Cases Monoclonal (n=143) 13 (9%) 26 (18%) 89 (62%) 2 (1%) 2 (1%) 11 (8%) 
     Age (years)* 66±13 (49-84) 69±13 (37-89) 69±13 (35-89) 65 & 95 79 & 80 71±9 (53-84) 
     Male/Female 4/9 15/11 50/39 1/1 0/2 7/4 
 Multiclonal (n=41) 2 (5%) 8 (19.5%) 23 (56%) - (0%) - (0%) 8 (19.5%) 
     Age (years)* 77 & 83 76±6 (65-82) 75±9 (57-89) - - 74±9 (56-81) 
     Male/Female 1/1 5/3 16/7 - - 6/2 
Age values expressed as *media ± one standard deviation (range) when n>2. MBL, monoclonal B-cell lymphocytosis; CLL, chronic 
lymphocytic leukemia/small lymphocytic lymphoma; B-CLPD, B-cell chronic lymphoproliferative disorders other than CLL or MBL. 
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Supplementary Table 2. Distribution of subjects included in the study and their corresponding CLL and non-CLL like B 
cell clones, according to diagnosis. 
  Diagnostic subgroups 
  CLL and CLL-like MBL Non-CLL B-CLPD and non-CLL MBL* 
  MBLlo MBLhi CLL MBLlo MBLhi Non-CLL 
Cases Monoclonal (n=143) 13 (87%) 26 (76.5%) 89 (80%) 2 (100%) 2 (100%) 11 (58%) 
 Multiclonal (n=41) 2 (13%) 8 (23.5%) 23 (20%) - (0%) - (0%) 8 (42%) 
 Total (n=184) 15 34 112  2 2 19 
B cell clones Monoclonal (n=143) 13 (48%) 26 (50%) 89 (77%) 2 (40%) 2 (50%) 11 (44%) 
 Multiclonal (n=85) 14 (52%) 26 (50%) 26 (23%) 3 (60%) 2 (50%) 14 (56%) 
 Total (n=228) 27 52 115 5 4 25 
CLL, chronic lymphocytic leukemia/small lymphocytic lymphoma (n=115 clones); MBL, monoclonal B-cell lymphocytosis (n=88 clones: 79 CLL-like MBL 
clones and 9 non-CLL-like MBL clones); B-CLPD, B-cell chronic lymphoproliferative disorders other than CLL (n=25 clones). 
*Patients other than CLL included the following diagnoses: HCL, hairy cell leukemia (n=1 clone); MZL, marginal zone lymphoma (n=17 clones); MALT, 
lymphoma of mucosa-associated lymphoid tissue (n=7); MCL, mantle cell lymphoma (n=3 clones); FL, follicular lymphoma (n=4 clones); DLBCL, diffuse 
large B-cell lymphoma (n=1 clones); LPL, lymphoplasmacytic lymphoma (n=1 clone). 





Supplementary Table 3. Diagnosis, differential immunophenotypic/IGHV features and cytogenetic alterations of 
the coexisting aberrant B-cell populations from multiclonal MBL, CLL and other B-CLPD cases (n=41). 
Case 
ID 
Phenotype of population 1 (% from 
WBC; compatible diagnosis) 
V(D)J rearrangement-MS† 
iFISH 
Phenotype of population 2 (% from 
WBC; compatible diagnosis) 
V(D)J rearrangement-MS† 
iFISH* 
1 FSC/SSClo CD19++ CD5+ CD20lo 
(62.9%; CLL) 
V3-30(D3-9)J6-UM 
ND FSC/SSCint CD19+hi CD5- CD20+ 
(4.1%; Non-CLL-like MBLhiMZL) 
V1-2(D5-5)J4-UM 
ND 
2¶ FSC/SSClolo FMC7lo CD23+ CD5+ 




FSC/SSClolo FMC7lo CD23+ CD5+ 





3 FSC/SSClo CD19+ lo CD5+ CD79blo 
FMC7- (26.5%; CLL) 
V1-3(D1-26)J3-M 
ND FSC/SSCint CD19lo+ CD5het CD79b- 
FMC7+ (25.7%; CLL) 
V4-34(D2-15)J3-M 
ND 





FSC/SSClolo CD20lo CD79bloCD5+ 
(0.6%; CLL-like MBLlo) 
V1-69(D3-3)J3-UM 
NDª 
5 FSC/SSCloloCD20lo CD5+ CD43+ 




FSC/SSClohiCD20+ CD5- CD43- 




6 FSC/SSClolo CD20lo FMC7- CD5+ 
CD23+ (33%; CLL) 
V4-34(D4-23)J2-M 
del(13q14.3) (96%) FSC/SSClolo CD20lo FMC7- CD5+ 
CD23+ (10.6%; CLL-likeMBLhi) 
V3-11(D6-19)J4-M 
del(13q14.3) (96%) 
7 FSC/SSCloCD19+ lo CD20lo CD5+ 
(34.6%; CLL) 
V4-39(D3-3)J6-UM 




8 FSC/SSClo CD19lo CD43- CD5+ 
CD25+ IgM+ CD27+ CD11c+/het 
(50.2% CLL) 
V1-3(D5-5)J5-M 
ND FSC/SSClo CD19+ CD43+ CD5hi 
CD25hi IgMhi CD27hi CD11c+ (5% CLL-
like MBLhi ) 
V3-53(D2-8)J6-M 
ND 
9 FSC/SSClo+ CD5+ CD20lo CD43- 
(12.6%; CLL-like MBLhi) 
V3-23(D5-12)J6-UM 
+12 (87%) FSC/SSClo+ CD5+ CD20lo CD43+ 
(3%; CLL-like MBLhi) 
V4-39(D6-13)J5-UM 
+12 (93%) 
10 FSC/SSClolo CD22lo CD23+ CD5+ 
(54.6%; CLL) 
Not found 
del(13q14.3) (96%) FSC/SSClolo CD22lo CD23+ CD5+ 
(4.1%; CLL-like MBLhi) 
V3-72(D2-2)J5-M 
ND 
11¶ FSC/SSClo CD19+ lo CD5+ CD79blo 
FMC7- (0.6%; CLL-like MBLlo ) 
V3-23(D5-12)J6-UM 
ND FSC/SSClo CD19+ + CD5+ CD79blo 




12 FSC/SSCloCD19+lo CD5+ CD20lo 
(89%; CLL) 
V4-39(D1-7)J3-UM 
ND FSC/SSCloCD19+ lo CD5+ CD20lo 
(0.1%; CLL-like MBLlo) 
V3-21(D6-13)J4-UM 
ND 
13 FSC/SSCloCD19+ lo CD20lo FMC7- 
CD5+ (49.9%; CLL) 
V5-51(D2-15)J4-UM 
ND FSC/SSCloCD19+ lo CD20lo FMC7- 
CD5+ (40.8%; CLL) 
V4-34(D3-10)J4-UM 
ND 
14¶ FSC/SSClo+d CD20lo CD5+ CD22lo 





FSC/SSCloloCD20lo/het CD5+ CD22lo 




15¶ FSC/SSCloCD19lo+ CD5- (11%; CLL-
like MBLhi) 
V3-23(D3-22)J6-UM 




16¶ FSC/SSChi CD19loCD38++CD10+ 
cBcl2+ sIg- c+ 




+18q21 (95%)  
+8q24 (92%) 
FSC/SSClo CD19+CD38-CD10-+ 
(2.5%;  Non-CLL FL) 
V3-23(D5-12)J6-UM 
t(14;18) (90%);  
+8q21 (90%)  
+18q21 (87%) 
17 FSC/SSCloCD19+ + CD5+ CD20lo 
CD11c- (59.3%; CLL) 
V1-46(D3-3)J4-UM 
ND FSC/SSClo CD19+ Ig- CD5- CD20hi 






18¶ FSC/SSCloCD19+ CD5+ lo (15.6%; 
CLL-like MBLhi) 
V3-15(D3-3)J4-M 
ND FSC/SSCloCD19+ CD5+ lo (10.1%; 
CLL-like MBLhi) 
V3-30(D5-12)J4-M 
+12 (19%);  
del(13q14.3) (32%) 
19¶ FSC/SSCloCD19+lo CD20lo CD5+ 
(44%; CLL) 
V3-30(D5-12)J4-M 
del(13q14.3) (80%) FSC/SSCloCD19+ loCD20lo CD5+ 




20 FSC/SSCloCD19+ loCD20lo CD5+ 
(35.6%; CLL) 
V4-34(D3-10)J6-M 
+12 (75%);  
 
FSC/SSCloCD19+ lo CD20lo CD5+ 




21 FSC/SSClohi FMC7+ CD5- CD23- 
CD43- (5.2%; Non-CLLMZL) 
V4-61(D7-27)J4-M 
ND FSC/SSClolo FMC7- CD5+ CD23+ 
CD43+ (2.3%;  CLL-like MBLlo) 
V3-21(D2-2)J6-M 
ND 
22 FSC/SSClo+ CD5+ CD20lo CD79blo 
(6.4%; CLL-like MBLlo) 
V3-74(D3-10)J4-M 
NDª FSC/SSCloloCD5+ CD20lo CD79b- 
(0.6%; CLL-like MBLlo) 
V4-59(D3-10)J6-M 
ND 
23 FSC/SSCloCD19+ lo CD22lo CD23+ 
CD5+ (11.5%; CLL-like MBLhi) 
V4-34(D5-24)J4-M 
ND FSC/SSCloCD19+ lo CD22lo CD23+ 
CD5+ (3.8%; CLL-like MBLhi) 
V3-33(D6-19)J2-M 
 ND 
24 FSC/SSClolo CD20lo FMC7- CD5+ 
CD23+ (21.1%;  CLL-like MBLhi) 
V5-51(D5-5)J4-M 
+12 (93%) FSC/SSClolo CD20lo FMC7- CD5+ 
CD23+ (8.7%; CLL-like MBLhi) 
V4-30-4(D2-2)J4-M 
ND 
25 FSC/SSCloCD19+ lo CD5het CD20lo 
(17.8%;  CLL-like MBLhi) 
V5-51(D3-3)J4-UM 
+12(76%);  t(14q32) 
(52%) 
FSC/SSCloCD19+ lo CD5lo CD20lo 
(2.6%;  CLL-like MBLhi) 
V1-69(D6-13)J6-UM 
ND 
26 FSC/SSClo+ CD5+ CD20lo CD43+ 
(23%; CLL-like MBLhi) 
V4-39(D3-3)J5-UM 
del(13q14) (15%);  
del(13q14.3) (15%) 
FSC/SSClolo CD5+ CD20lo CD43- 
(3.7%; CLL-like MBLhi) 
V1-69(D5-5)J4-UM 
ND 
27¶ FSC/SSCloloCD20lo CD79blo CD5+ 
(10%; CLL-like MBLhi) 
V3-7(D5-12)J3-M 
del(13q14) (98%);  
del(13q14.3) (98%) 
FSC/SSCloloCD20lo CD79blo CD5+ 
(0.6%; CLL-like MBLlo) 
V3-23(D6-6)J4-M 
ND 
28 FSC/SSCloCD19+ + CD5+ CD20lo 
CD22- (68%; CLL) 
V3-48(D4-17)J4-M 
del(13q14) (95%);  
del(13q14.3) (87%) 
FSC/SSCloCD19+  + CD11c+ CD5het 




29¶ FSC/SSClolo CD19lo, CD20lo CD79b- 
CD43+ (36.4%; CLL) 
V3-48(D3-10)J4-M 
ND FSC/SSClohi CD19+, CD20hi CD79b+ 
CD43- (16.7%; Non-CLLMALT) 
V3-15(D4-17)J4-M 
del(17p13) (91%) 
30 FSC/SSCloloFMC7lo CD5+ CD79b- 
CD23+ CD43+ (33.7%; CLL) 
V4-34(D3-10)J4-UM 
t(14q32) (98%)  FSC/SSClo+ CD5- CD11c- 




31¶ FSC/SSCintlo CD23+ CD5+ CD11c+ 
(24%; CLL) 
V3-33(D2-15)J5-UM 




32¶ FSC/SSCintCD19+ + CD20+ CD5- 
(17.7% Non-CLLMZL) 
V4-39(D6-19)J4-M 
ND FSC/SSCloCD19+ lo CD5+ CD20lo 
(3.2%;  CLL-like MBLhi) 
V4-34(D6-19)J4-M 
ND 
33 FSC/SSCloCD19+dlo CD5+ CD20lo  
(65.3%; CLL) 
V2-26(D3-3)J5-M 
del(13q14.3) (81%) FSC/SSCloCD19hi+ CD5+ CD20hi 
(12.5%; Non-CLL MZL) 
V3-53(D2-15)J2-M 
t(14q32) (28%)  
34¶ FSC/SSClo+ CD19+ CD20hi CD22+ 
CD38- CD11c- CD25+ (65.8%; Non-
CLLMALT) 
V3-7(D2-21)J4-M 
ND FSC/SSClo+ CD19+ CD20hi CD22+ 




35¶ FSC/SSClolo CD20lo FMC7- CD5+ 
CD23+ (55.3%; CLL) 
V3-9(D3-3)J3-UM 
ND FSC/SSClolo CD20lo FMC7- CD5+ 
CD23+ (9.8%;  CLL-likeMBLhi) 
V3-21(D2-2)J6-M 
ND 
36 FSC/SSCinthiCD5+ CD11c+ FMC7lo 
(46%; Non-CLL MZL) 
V1-2(D6-6)J5-UM 




37¶ FSC/SSChi CD103+ CD25+ CD11c+ 
(21%; Non-CLLHCL) 
V3-30(D3-3)J5-UM 




38¶ FSC/SSCloCD19lo+ CD5+ CD20+ 
CD23- (38.6%; Non-CLL MZL) 
V3-21(D6-13)J6-UM 
+3q27 (89%) FSC/SSCloCD19hilo CD5+ CD20lo 
CD23+ (6.3%; CLL-likeMBLhi) 
V3-48(D3-3)J3-M 
del(13q14.3) (18%) 
39 FSC/SSClolo CD19+, CD20lo CD79b- 
CD43+ (24%; CLL-like MBLhi) 
V1-3(D3-3)J6-UM 
ND FSC/SSClolo CD19+ CD20lo FMC7- 






40¶ FSC/SSCloloCD20lo CD5+ CD22lo 




FSC/SSCloloCD20lo/het CD5+ CD22lo 
CD23+ FMC7- (43.1%; CLL) 
V3-21(D4-23)J4-M 
del(13q14.3) (30%) 
41 FSC/SSCintlo CD5+ CD19+ CD11c- 
(87.1%; Non-CLL MCL) 
V3-21(D3-3)J6-UM 





CLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; HCL, hairy cell leukemia; LPL, lymphoplasmacytic lymphoma; MZL, marginal zone 
lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MALT, B-cell lymphoma of mucosa-associated lymphoid tissue. + indicates antigen 
expression at normal levels; -, absence of expression; het, heterogeneous antigen expression; hi, high antigen expression; lo, low antigen expression; 
int, intermediate scatter; c, cytoplasmatic antigen expression. †MS, mutational status (UM, unmutated; M, mutated), *FISH was performed on interphase 
nuclei from FACS-purified cells; ND: no chromosomal alterations detected by iFISH for the probes studied; NA: not analyzed. An additional B-cell clone 
(population 3) was detected by interphase FISH in case 2 (FSC/SSClolo CD23lo CD5lo CD43lo CD11clo; 0.7%, CLL-like MBLlo; NDa), case 25 
(FSC/SSCloCD19+ + CD5hi CD20lo; 2.4%, CLL-like MBLhi; +12(66%)) and case 37 (FSC/SSClolo CD5+; 0.2%, CLL-like MBLlo; NDª)aThepercentage 
of B-cells from this subpopulation was very low and only allowed some iFISH probes (13q14, 13q14.3, 17p13.1 and 11q22.3). The presence of genetic 
abnormalities in one population was always evaluated in the other coexisting population. 




Supplementary Table 4. Cytogenetic features of non-CLL like B-cell clones from monoclonal cases. 
Clone type Type of cytogenetic changes / % aberrant B-cells analyzed by iFISH 
Non-CLL-like MBLhi (MZL) trisomy 12+ (80%); and  t(14q32)+ (35%) 
Non-CLL (FL) del(13q14.3)+ (18%); 3 copies of IGH gene (85%)*
Non-CLL (FL) t(14;18)+ (89%); and t(8;14)+ (78%); polysomy 
Non-CLL (MCL) t(11;14)+ (93%) 
Non-CLL (MALT) t(14q32)+ (94%) 
Non-CLL (MZL) t(14q32)+ (94%); 3 and 4 copies of IGH gene (53% and 37%, respectively) 
 
Only cytogenetically altered clones are shown; cytogenetically non-altered clones from monoclonal cases 
included non-CLL MZL (n=5; 2 MBLlo, 1 MBLhi and 2 MZL), MALT-lymphoma (n=1), MCL (n=1), DLBCL (n=1) 
and LPL (n=1). CLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MBL, monoclonal B-cell 
lymphocytosis; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; LPL, lymphoplasmacytic 
lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone B-cell lymphoma; MALT, B-cell lymphoma of 
mucosa-associated lymphoid tissue; * t(14;18)+ by molecular studies; ND, not detected ; NA, not analyzed. 
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Supplementary Table 5. Molecular characteristics of the B-cell receptor 




Non-CLL B-cell clones 
n=34 clones 
 Multiclonal Monoclonal 
HCDR3 length* (N. of aa) 14 (8-26) 16 (7-22) 
VH families 
VH1 4/19 (21%) 3/15 (20%) 
VH3 12/19 (63%) 8/15 (53%) 
VH4 3/19 (16%) 2/15 (13%) 
VH5 0/19 (0%) 1/15 (7%) 
VH6 0/19 (0%) 1/15 (7%) 
   
DH families 
DH1, DH4, DH7 5/19 (26%) 2/14 (14%) 
DH2 3/19 (16%) 4/14 (29%) 
DH3 4/19 (21%) 2/14 (14%) 
DH5 2/19 (11%) 5/14 (36%) 
DH6 5/19 (26%) 1/14 (7%) 
   
JH genes 
JH1, JH2, JH3, JH5 7/19 (37%) 3/15 (20%) 
JH4 8/19 (42%) 7/15 (47%) 
JH6 4/19 (21%) 5/15 (33%) 
   
   
LCDR3 length* (N. of aa) 9 (9-11) 9 (8-12) 
VK families 
VK1 4/11 (36%) 3/12 (25%) 
VK2 2/11 (18%) 1/12 (8%) 
VK3-4 5/11 (46%) 8/12 (67%) 
   
JK genes 
JK1, JK3, JK5 5/11 (42%) 5/11 (45%) 
JK2 2/11 (33%) 2/11 (21%) 
JK4 4/11 (25%) 4/11 (34%) 
   
Vλ families 
Vλ3 1/3 (33%) 1/1 (100%) 
Other 2/3 (67%) 0/1 (0%) 
   
Jλ genes 
Jλ2 2/3 (67%) 1/1 (100%) 
Jλ3 1/3 (33%) 0/1 (0%) 
 
Results expressed as number of B-cell clones from all clones in the corresponding 
group (percentage) or as *median (range). Non-CLL, clones mimicking or compatible 
with B-cell chronic lymphoproliferative disorders other than chronic lymphocytic 
leukemia; BCR, B-cell receptor; HCDR3, heavy chain complementarity-determining 




Supplementary Table 6.  Monoclonal cases with B-cell clones sharing HCDR3 sequences of the 
same length (± 1 aminoacid) and belonging to identical or evolutionary highly-related VH families. 
Monoclonal Cases ID VH families HCDR3 length AA composition of HCDR3  (% homology)#
149 V3-48 8 W_IDRGRLRS_C 
)25( 
158 V3-11 8 W_YDGSYFRA_C 
66 V3-7 9 W_IDRYVYARG_C 
)44( 
136 V3-7 9 W_YDGWYGARG_C 
113 V3-74 9 W_RQLDMYSLA_C 
)11( 
121 V3-64 9 W_VDRTGMDVA_C 
92 V3-23 12 W_YLDGRQLWSYAK_C 
)33( 
153 V3-23 12 W_IFDDGFTKDVAK_C 
16 V1-2 13 W_IFDGLNTDYGAAR_C 
)31( 
18 V1-2 13 W_YFDAQWLVLENAR_C 
201 V4-34 13 W_FLDRGFHWGGYYA_C 
)23( 
206 V4-34 13 W_PFDTNSRESQGWA_C 
190 V4-34 14 W_YDIRYYDFSAPAPA_C 
)29( 
214 V4-34 14 W_YTLIGDKGGYYVRA_C 
205 V4-59 14 W_YLDNGGWPDISARG_C 
)50( 
218 V4-61 14 W_PGWFDDHGEGRYAK_C 
124 V3-23 14 W_DIQPNAFIKFYDDA_C 
)29( 
145 V3-23 14 W_DFSCYGVIFHCCRA_C 
24 V1-2 15 W_SFDSQGSRDLEMRYA_C 
)60( 
35 V1-2 15 W_YFDLQGWRDVELRYG_C 
125 V3-7 16 W_LDFTARYLPYADLASA_C )31( 
12 
 
147 V3-7 16 W_YESSISTTSCPSCQSG_C 
105 V3-23 16 W_YFDADGYGGTPRDKDT_C 
)35( 
142 V3-23 17 W_IFDTDVIQKTRTLAKDA_C 
142 V3-23 17 W_FDIRTLATVIQKDTAKD_C 
)35( 
104 V3-23 18 W_FDILPSTYNWNSGGAAKD_C 
151 V3-30 17 W_DYFILPPGVGGIASGSM_C 
)18( 
120 V3-30 18 W_AIFSWNDACSSMTRPHCS_C 
132 V3-30 19 W_VGMDEFRYYLDFGMAGKIA_C 
)37( 
150 V3-30 19 W_SDGGIGTCCQGLDTSGNRA_C 
96  V3-21 20  W_YYGMDVATGHSHHPVRESAR_C 
)45( 
155  V3-48 20  W_YYGMDVGYPDSSPGYDFWAR_C 
196 V4-34 20 W_VLDYYGYYTERRYYPSDVRG_C 
)40( 
202 V4-34 20 W_YFDFPPYYGSGSYLIGAARG_C 
 
                    (Continuation) 
Monoclonal Cases ID VH families HCDR3 length AA composition of HCDR3  (% homology)#
198 V4-34 20 W_VMDYYGYYRRTEGSTGYARG_C 
)50( 
202 V4-34 20 W_YFDPFPYYGSGSAYGLIARG_C 
155 V3-48 20 W_YYGMDVPDYDFWSGYSPGAR_C 
)71( 
130 V3-48 21 W_YYGMDVYSYYYYDFWSGYDAR_C 
96  V3-21 20 W_VMDYGYGHTASHHPVRESAR_C 
)35( 
114 V3-21 21 W_YFDTTLYSCTSSEGGLGYCAR_C 
130 V3-48 21 W_VMDGYYYYYSYGYWSFYDARD_C 
)48( 
114 V3-21 21 W_YFDTTLYSTSCSCLGYGGARE_C 
13 
 
22 V1-69 21 W_MDVGYYYYYYTGVAGVVYARE_C 
)67( 
39 V1-69 21 W_GYYYYYYYMDVLMTNWGTARD_C 
22 V1-69 21 W_MDVYYYYYGGTYAVGYEVVAR_C 
)48( 
31 V1-69 21 W_FDIRPNDAGSYWIDYYGGNAR_C 
31 V1-69 21 W_FDIRPNDAYSWGNYDYIGGAR_C 
)43( 
39 V1-69 21 W_MDVYYYYYYYWGLMTNGDTAR_C 
143 V3-30 21 W_YFDSHGTYYYDNSHGPNVSAR_C 
)28( 
138 V3-30 22 W_VMDDGGDFWSGYYYDLKTAYAR_C 
114 V3-21 21 W_YFDTTLCYSSTSCLGYGGARE_C 
)42( 
110 V3-21 22 W_PFDNWLYEDPLNFDWGRRNARD_C 
114 V3-21 21 W_YFDTTLCYSSTSCGYLGGEAR_C 
)42( 
157 V3-21 22 W_VMDYYYGIYMEGLSAWLLRARG_C 
110 V3-21 22 W_PDNWFYPLDEWLRNGNFDRDAR_C 
)36( 
157 V3-21 22 W_VDYYYGMYGIELMWLLSARGAR_C 
110 V3-21 22 W_PFDYNWLLEDPWDFNGNRRARD_C 
)41( 
93 V3-11 22 W_YFDPDDKLSGYYFWYYDRPARD_C 
157 V3-21 22 W_VMDYYGYYIGGRLSAWLLMEAR_C 
)32( 
93 V3-11 22 W_YFDLPDDKGYYDPRYYDFWSAR_C 
26 V1-69 22 W_DVMGYYYYTVYITIFGVVTTTA_C 
)32( 
34 V1-69 22 W_QHYFGVAESVYSTYYYDSSRGA_C 
26 V1-69 22 W_YYGMDVYYYTVVVFGTTTITIA_C 
)50( 
27 V1-69 23 W_YYGMDVNTVYSGSWRADGGYDFA_C 
34 V1-69 22 W_EYFQHAGVYYYDSSVYGSSTAR_C 
)23( 
27 V1-69 23 W_NYYGMDVVSTYDFWSGYADGGAR_C 
14 
 
129  V3-11 23  W_YYYYGMDVRRDDFWSGYRIYARD_C 
)48( 
141  V3-48 23  W_YYYYGMDVNTANDIVVVPADARD_C 
27 V1-69 23 W_MDVGYYNVYSTYDFWSGGGARAD_C 
)69( 
15  V1-69 24  W_MDVYYYYDVHKGYDFWSGQYARAE_C 
Aminoacids with analogous side-chain polarity (highlighted in gray): L,F; A,V; I,L; K,R; L,V;  L,M; L,C; T,S; A,I; D,E; I,M; V,C; L,F; M,F; 




Supplementary Table 7. Peripheral blood (PB) B-cell counts and BCR features of multiclonal vs. 
monoclonal CLL-like and non-CLL-like B-cell clones 










N. of PB clonal B cells (x106/L)* 2,675 (0.6-71,485)a 10,956 (0.1-369,288) 4,375 (85-156,168) 4,771 (54-41,221) 
% of PB clonal B cells from WBC* 13% (0.1%-89%)a 45% (0.001%-97%) 13% (0.5%-87%) 41% (1%-73%) 
MBLlo B-cell clones 14/66 (21%)a 13/128 (10%) 3/19 (16%) 2/15 (13%) 
MBLhi B-cell clones 26/66 (39%)a 26/128 (20%) 2/19 (10%) 2/15 (13%) 
CLL B-cell clones 26/66 (39%)a 89/128 (69%) NA NA 
CLL-stage A clones 12/66 (18%)a 53/128 (41%) NA NA 
CLL-stage B/C clones 8/66 (12%)a 36/128 (28%) NA NA 
Non-CLL B-cell clones NA NA 14/19 (74%) 11/15 (73%) 
IGHV mutated B-cell clones 40/66 (61%) 76/124 (61%) 11/19 (58%) 8/15 (53%) 
% alignment of IGHV aa sequences between 
coexisting B-cell clones 
51% (38%-79%) NA 62% (46%-76%)# NA 
% alignment of IGHV aa sequences between 
each B-cell clone and the other clones 
52% (31%-100%)a 50% (29%-100%) 51% (32%-89%)a 49% (33%-86%) 
Results expressed as number of B-cell clones and percentage between brackets or as *median value (range). PB, peripheral blood; WBC, white blood 
cells; CLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MBLlo, low count monoclonal B-cell lymphocytosis; IGHV, immunoglobulin heavy 
chain variable region genes; CLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MBLhi, clinical monoclonal B-cell lymphocytosis; aa, 
aminoacids. NA, not appropriate.#Both coexisting B-cell clones showed Non-CLL-like phenotype (n=4 cases) or the majority B-cell clone showed Non-







Supplementary Figure 1. Absolute number of CLL-like MBLlo, CLL-like MBLhi, CLL, non-CLL MBL 
and non-CLL B-cell clones per µL of peripheral blood in multiclonal vs monoclonal cases 
distributed according to diagnosis. Boxes extend from the 25th to the 75th percentiles, the lines in the 
middle represent median values (50th percentile). Vertical lines represent the highest and lowest values that 
are not outliers or extreme values (being outliers and extreme values those values that lie more than 1.5- 
and 3- fold the length of the box). The adjacent table compiles the median number and range of each 
subgroup of CLL-like and non-CLL like clonal B-cells/µL of peripheral blood and the exact P-values 
obtained after comparing multiclonal vs monoclonal cases (Mann-Whitney U test) for the MBLlo, MBLhi and 
CLL subgroups. NS: no statistical significant differences were detected (P≥0.05). 
 
